Interim Report Q2 2022

Continued growth in the licensing business and in our product portfolio

  • Revenue 59.9 MSEK (46.0)
  • EBITDA -3.8 MSEK (1.8)
  • Cash flow -1.9 MSEK (5.5)
Read the report

Continued growth in the licensing business and in our product portfolio

Bactiguard Holding AB (publ) published the interim report for the second quarter on Thursday July 14, 2022 at 8:00 CET.

In connection with this, an audiocast for investors, analysts and media was held at 11:00 CET on July 14, where CEO Anders Göransson and CFO Carin Jakobson presented the interim report and answered questions.

Presentation (PDF)

Continued growth in the licensing business and in our product portfolio

Bactiguard’s Annual Report 2021 <br /> - Accceleration with<br /> the patient in focus

Bactiguard’s Annual Report 2021
- Accceleration with
the patient in focus

Exciting future for Bactiguard with CEO
Anders Göransson

Bactiguard’s CEO Anders Göransson speaks with excitement about the future of the company and the growth journey that lays ahead. “Hearing the great feedback from our partners and patients makes me realise that I made the right choice to join Bactiguard”, says Anders Göransson.

Read the interview where Anders Göransson shares his thoughts on where he sees the company heading and what he thinks makes a great leader.

 

Interim Report Q2 2022

Bactiguard Holding AB (publ) published the interim report for the second quarter on Thursday July 14, 2022 at 8:00 CET.

Press & Investor Relations

Carin Jakobson
Carin Jakobson
CFO

Employed 2022

Born: 1974

Education: MSc in Economics Linnaeus University

Background: CFO positions at, among others, Stille, Sivers IMA and Rolling Optics

Other assignments:

Shareholdings:

Contact us